会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • SURGICAL GUIDING AND POSITION SYSTEM
    • 手术指导和定位系统
    • US20140296871A1
    • 2014-10-02
    • US14229620
    • 2014-03-28
    • Chieh-Hsiao ChenShinn-Zong LinHorng-Jyh Harn
    • Chieh-Hsiao ChenShinn-Zong LinHorng-Jyh Harn
    • A61B19/00
    • A61B34/30A61B34/20A61B90/11A61B2017/00026A61B2034/2048A61B2090/3735
    • The present invention discloses a surgical guiding and positioning system, comprising: a global information device, a local information device, and a computing device. The global information device is capable of collecting an overall information of a surgical site before a surgical procedure begins. The local information device can comprise a surgical device including at least one sensor and provide a real-time information of a section of the surgical site. The computing device is capable of calculating a position data of the surgical device in the surgical site by comparing the overall information and the real-time information. Therefore, the present invention is capable of providing the real-time guidance and monitoring during a surgical procedure so that the surgeon can acquire precise real-time information of the surgical site and perform the surgery efficiently.
    • 本发明公开了一种外科引导和定位系统,包括:全局信息设备,本地信息设备和计算设备。 全球信息设备能够在外科手术开始之前收集手术部位的总体信息。 本地信息装置可以包括外科装置,其包括至少一个传感器并提供手术部位的一部分的实时信息。 计算装置能够通过比较总体信息和实时信息来计算外科手术部位的手术装置的位置数据。 因此,本发明能够在外科手术过程中提供实时指导和监测,使得外科医生可以获得手术部位的精确实时信息并有效地进行手术。
    • 10. 发明申请
    • Gamma-butyrolactone compound and pharmaceutical composition thereof
    • γ-丁内酯化合物及其药物组合物
    • US20100028461A1
    • 2010-02-04
    • US12378504
    • 2009-02-17
    • Shinn-Zong LinHorng-Jyh Harn
    • Shinn-Zong LinHorng-Jyh Harn
    • A61K33/24A61P35/00
    • A61K36/23
    • A γ-butyrolactone compound as shown in Formula (I) and pharmaceutical composition thereof: wherein X═N, O, S, Se; and A and B are selected from substituents having the following formula: wherein R1, R2, R3, R4, and R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group. The γ-butyrolactone compound and pharmaceutical composition thereof butyrolactone have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung cancer, malignant glioblastoma or colorectal carcinoma, and are cytotoxic with high specificity to inhibit Paclitaxel-resistant tumour cells at later stage of chemotherapy without any damage on normal cells.
    • 式(I)所示的γ-丁内酯化合物及其药物组合物:其中X-N,O,S,Se; A和B选自具有下式的取代基:其中R1,R2,R3,R4和R5选自氢原子,卤素原子,羟基,巯基,氨基,烷氧基 和硝基。 γ-丁内酯化合物及其药物组合物丁内酯对肝癌,卵巢癌,乳腺癌,肺癌,恶性胶质母细胞瘤或结肠直肠癌具有抑制作用,具有高度特异性的细胞毒性,可在化疗后期抑制紫杉醇耐药肿瘤细胞,无 对正常细胞的任何损伤。